Rich Pharmaceuticals Inc. (fka RCHA)

[Dragonwing]

David Chou, Ph.D. & Richard Salvador Ph.D.


David Chou, Ph.D. serves on the Company’s Board of Directors.

Dr. Chou is a pharmaceutical development expert with more than 25 years of experience and he has led numerous development projects from pre-clinical evaluation stage to product commercialization. Prior to joining Rich Pharmaceuticals, Mr. Chou was the Chief Product Development Officer at Biosuccess Biotech where he led the product development and manufacturing activities for various indications. Before his career with Biosuccess Biotech, Mr. Chou was the Head of CMC (a Vice President level position) at SBIO, Inc. from 2010 to 2012. While at SBIO, he managed the technical development of 4 clinical stage products and made significant contributions to the success of product out-licensing deals with a total value of more than $500 million. From 1998 to 2010, Mr. Chou held director level positions in pharmaceutical development fields at various biopharmaceutical companies including Neurobiological Technologies, PharmaEngine, Oculex and SUGEN and his development portfolios included Sutent® currently marketed by Pfizer and OZURDEX® marketed by Allergan. Prior to his biotech career, Mr. Chou held various management positions at Hoffmann La-Roche for more than 12 years. At Roche, his development team contributed and submitted more than 20 INDs and 6 full NDAs including marketed products such as Xeloda® (Capecitabine), Xenical® (Orlistat) and Hivid® (Zalcitabine). Mr. Chou received a Ph.D. degree in Chemistry from the City University of New York.

http://www.richpharmaceuticals.com/wp-content/uploads/2014/03/Update-on-Recent-Activities.pdf


Richard Salvador Ph.D. Chief Clinical Officer

Dr. Salvador has worked for 25 years at Hoffmann-La Roche Inc. rising to Vice-President of International Preclinical Development and Deputy to the President of International R&D. Dr. Salvador managed the Departments of Clinical Pharmacology, Toxicology and Pathology, Drug Metabolism, Pharmaceutical Research and Development, and Bioprocess Development. He is a member of the American Society of Pharmacology and Experimental Therapeutics, the American Chemical Society, the American Association of Pharmaceutical Scientists, and the New York Academy of Science.

http://www.bloomberg.com/research/stocks/people/person.asp?personId=254492923&ticker=RCHA&previousCapId=130695544&previousTitle=RICH%2520PHARMACEUTICALS%2520INC